Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.44 |
| ▸ | INSR | P06213 | 5/20 | 0.42 |
| ▸ | IGF1R | P08069 | 5/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | STK25 | O00506 | 1/20 | 0.40 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CASK | O14936 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | MUSK | O15146 | 1/20 | 0.40 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27031685 | 0.94 | EGFR (0.45) | EGFRINSRIGF1RALKBRD4 | |
| SCHEMBL24351864 | 0.91 | EGFR (0.55) | EGFRINSRIGF1RALKCRBN | |
| SCHEMBL24351643 | 0.91 | CRBN (0.48) | EGFRALKCRBNPLK4PTK2 | |
| SCHEMBL27031703 | 0.90 | EGFR (0.53) | EGFRIGF1RALKBRD4CRBN | |
| SCHEMBL24351658 | 0.90 | EGFR (0.43) | EGFRINSRIGF1RALKCRBN | |
| SCHEMBL24352065 | 0.89 | EGFR (0.45) | EGFRINSRIGF1RALKBRD4 | |
| SCHEMBL27048810 | 0.88 | EGFR (0.49) | EGFRIGF1RALKBRD4CRBN | |
| SCHEMBL27048853 | 0.86 | EGFR (0.55) | EGFRINSRIGF1RALKCRBN | |
| SCHEMBL24351867 | 0.85 | ALK (0.47) | EGFRALKCRBNPLK4PTK2 | |
| SCHEMBL27031713 | 0.85 | EGFR (0.46) | EGFRINSRIGF1RALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| WO-2022068849-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | EGFR 1/4885INSR 1417/4885IGF1R 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.